ITER

COM:ITERIONTHERAPEUTICS

Iterion Therapeutics

Add to Watchlist
  • Privately Held

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Iterion Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in-class small molecule inhibitor of TBL1 (Transducin Beta-Like Protein 1), a novel downstream target of the canonical Wnt/beta-catenin signaling pathway.